Which Patients with Chronic Hepatitis B Are More Likely to Relapse after Interferon Alpha-Induced Hepatitis B e Antigen Loss in Korea?

Journal of Clinical Gastroenterology

Volumn 38, Issue 2, 2004, Pages 124-129

  Song, Byung Cheol ^a   Suh, Dong Jin ^b,c   Lee, Han Chu ^b   Chung, Young Hwa ^b   Lee, Yung Sang ^b  

^a Jeju National University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Asan Medical Center   (South Korea)

Author keywords

Chronic hepatitis B; Endemic area; HBeAg loss; Interferon alpha; Relapse

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CAUCASIAN; CONTROLLED STUDY; ENDEMIC DISEASE; FEMALE; GENDER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION; KOREA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; RISK FACTOR;

ADOLESCENT; ADULT; AGE FACTORS; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; KOREA; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 1642539063     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200402000-00008     Document Type: Article

References (41)

1. Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology. 1988;95:1318-1325.
2. Perrillo RP, Regenstein FG, Peters MG, et al. Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. Ann Intern Med. 1988;109:95-100.
3. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? A statistical analysis of predictive factors. Hepatology. 1989;10:761-763.
4. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 1990;323:295-301.
5. Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med. 1991;114:629-634.
6. Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 1992;102:2091-2097.
7. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119:312-323.
8. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422-1427.
9. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 1997;113:1660-1667.
10. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971-975.
11. Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomized controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988;298-302.
12. Lok AS, Chung HT, Liu VW, et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroeterology. 1993;105:1833-1838.
13. Yuen MF, Hui CK, Cheng CC, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology. 2001;34:139-145.
14. Infante-Rivard C, Villeneuve JP, Esnaola S. A framework for evaluating and conducting prognostic studies: an application to cirrhosis of the liver. J Clin Epidemiol. 1989;42:791-805.
15. Martin P, Hann HW, Westerberg S, et al. Interferon-alpha 2b therapy is efficacious in Asian-Americans with chronic hepatitis B infection: a prospective controlled trial. Dig Dis Sci. 1998;43:875-879.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
17. Peto R, Pike MC. Conservation of the approximation (O-E)/E in the log rank test for survival data on tumor incidence data. Biometrics. 1973;29:579-584.
18. Cox DR. Regression models and life tables (with discussion). JR Stat Soc B. 1972;34:187-220.
19. Hoofnagle JH, Dusheiko GM, Schafer DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med. 1982;96:447-449.
20. Markovic S, Drozina G, Vovk M, et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology. 1999;46:2925-2930.
21. Perrillo RP, Campbell CR, Sanders GE, et al. Spontaneous clearance and reactivation of hepatitis B virus infection among male homosexuals with chronic hepatitis B. Ann Intern Med. 1984;100:43-46.
22. Davis GL, Hoofnagle JH. Reactivation of chronic hepatitis presenting as acute viral hepatitis. Ann Intern Med. 1985;102:762-765.
23. Gupta S, Govindarajan S, Fong TL, et al. Spontaneous reactivation in chronic hepatitis B: patterns and natural history. J Clin Gastroenterol. 1990;12:562-568.
24. Kornfeld H, Vande Stouwe RA, Lange M, et al. T-lymphocyte subpopulation in homosexual men. New Engl J Med. 1982;307:729-731.
25. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. New Engl J Med. 1981;305:1425-1431.
26. Lok ASF, Lai C, Wu PC, et al. Spontaneous hepatitis B antigen to anti-body seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology. 1987;92:1839-1843.
27. Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seronconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000;32:803-806.
28. Baker BL, Di Bisceglie AM, Kaneko S, et al. Determination of hepatitis B virus DNA in serum using the polymerase chain reaction: clinical significance and correlation with serological and biochemincal markers. Hepatology. 1991;13:632-636.
29. Loriot MA, Marcellin P, Bismuth E, et al. Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B. Hepatology. 1992;15:32-36.
30. Fong TL, Di Bisceglie AM, Gerber MA, et al. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology. 1993;18:1313-1318.
31. Han KH, Kim KH, Hong SP et al. Efficacy of prednisolone withdrawal followed by recombinant alpha interferon in patients with chronic active hepatitis B. Kor J Med. 1990;39:299-307.
32. Orito E, Ichida T, Sakugawa H, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology. 2001;34:590-594.
33. Lee SH, Han SH, Cho SC, et al. Distribution of HBV genotypes in patients with chronic HBV infection in Korea. Kor J Hepatol. 2001;7:373-380.
34. Cho IH, Song JY, Kim DK, et al. Prevalence of HBV genotypes in Korean patients with chronic hepatitis B. Kor J Hepatol. 2001;7:381-386.
35. Song BC, Kim BJ. Distribution of HBV genotype in various clinical outcome of HBV infection in Jeju island. Kor J Hepatol. 2003;9(Suppl. 3):S80.
36. Kao JH, Chen PJ, Lai MY, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000;118:554-559.
37. Chu CJ, Hussain M, Lok ASF. Hepatitis B virus genotype B is associated with early HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122:1756-1762.
38. Wai CT, Chu CJ, Hussain M, et al. HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology. 2002;36:1425-1430.
39. Chen RN, Liaw YF, Tsai SL, et al. HBV genotype is the major factor for durability of HBeAg responses to lamivudine. Gastroenterology. 2002;123:69.
40. Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology. 1984;86:230-235.
41. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995;13:29-60.